Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer

References

• Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int 2011;107:912–18.
   PubMed Web of Science ®Google Scholar
• Nativ O, Witjes JA, Hendricksen K, Cohen M, Kedar D, Sidi A, et al. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol 2009;182:1313–17.
   PubMed Web of Science ®Google Scholar
• Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583–92.
   PubMed Web of Science ®Google Scholar
• Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010;7:653–64.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BWG, Comperat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013. Eur Urol 2013;64:639–53.
   PubMed Web of Science ®Google Scholar
• Porter MP, Gore JL, Wright JL. Hospital volume and 90-day mortality risk after radical cystectomy: A population-based cohort study. World J Urol 2011;29:73–7.
   PubMed Web of Science ®Google Scholar
• Malmstrom P-U, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247–56.
   PubMed Web of Science ®Google Scholar
• Breau RH, Karnes RJ, Farmer SA, Thapa P, Cagiannos I, Morash C, et al. Progression to detrusor muscle invasion during urothelial carcinoma surveillance is associated with poor prognosis. BJU Int 2014;113:900–6.
   PubMed Web of Science ®Google Scholar
• See WA, Xia Q. Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin – impact of concomitant administration of dimethyl-sulfoxide on drug absorption and antitumor activity. J Natl Cancer Inst 1992;84:510–15.
   PubMed Web of Science ®Google Scholar
• Parsons CL, Boychuk D, Jones S, Hurst R, Callahan H. Bladder surface glycosaminoglycans – an epithelial permeability barrier. J Urol 1990;143:139–42.
   PubMed Web of Science ®Google Scholar
• Kohli AG, Kivimaee S, Tiffany MR, Szoka FC. Improving the distribution of Doxil (R) in the tumor matrix by depletion of tumor hyaluronan. J Control Release 2014;191:105–14.
   PubMed Web of Science ®Google Scholar
• Ranney D, Antich P, Dadey E, Mason R, Kulkarni P, Singh O, et al. Dermatan carriers for neovascular transport targeting, deep tumor penetration and improved therapy. J Control Release 2005;109:222–35.
   PubMed Web of Science ®Google Scholar
• Mugabe C, Matsui Y, So AI, Gleave ME, Baker JHE, Minchinton AI, et al. In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer. Clin Cancer Res 2011;17:2788–98.
   PubMed Web of Science ®Google Scholar
• Topazio L, Miano R, Maurelli V, Gaziev G, Gacci M, Iacovelli V, et al. Could hyaluronic acid (HA) reduce bacillus Calmette–Guerin (BCG) local side effects? Results of a pilot study. BMC Urol 2014;14:64.
   PubMed Web of Science ®Google Scholar
• Apodaca G. The uroepithelium: Not just a passive barrier. Traffic 2004;5:117–28.
   PubMed Web of Science ®Google Scholar
• Khandelwal P, Abraham SN, Apodaca G. Cell biology and physiology of the uroepithelium. Am J Physiol Renal Physiol 2009;297:F1477–501.
   PubMedGoogle Scholar
• Wientjes MG, Badalament RA, Wang RC, Hassan F, Au JLS. Penetration of mitomycin-C in human bladder. Cancer Res 1993;53:3314–20.
   PubMed Web of Science ®Google Scholar
• Rath-Wolfson L, Moskovitz B, Dekel Y, Kugel V, Koren R. Combined intravesical hyperthermia and mitomycin chemotherapy: A preliminary in vivo study. Int J Exper Pathol 2003;84:145–52.
   PubMed Web of Science ®Google Scholar
• Paroni R, Salonia A, Lev A, Da Pozzo LF, Cighetti G, Montorsi F, et al. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol 2001;52:273–8.
   PubMed Web of Science ®Google Scholar
• Coss RA, Linnemans WAM. The effects of hyperthermia on the cytoskeleton: A review. Int J Hyperthermia 1996;12:173–96.
   PubMed Web of Science ®Google Scholar
• Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: Effect of particle size. Cancer Res 2000;60:4440–5.
   PubMed Web of Science ®Google Scholar
• Au JL, Wientjes MG. Combination intravesical hyperthermia and chemotherapy for bladder cancer. Oncology (Williston Park). 2010;26:1155–60.
   Google Scholar
• Inman BA, Etienne W, Rubin R, Owusu RA, Oliveira TR, Rodriques DB, et al. The impact of temperature and urinary constituents on urine viscosity and its relevance to bladder hyperthermia treatment. Int J Hyperthermia 2013;29:206–10.
   PubMed Web of Science ®Google Scholar
• Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002;43:33–56.
   PubMed Web of Science ®Google Scholar
• Ware MJ, Tinger S, Colbert KL, Corr SJ, Rees P, Koshkina N, et al. Radiofrequency treatment alters cancer cell phenotype. Sci Rep 2015;5:12083.
   PubMed Web of Science ®Google Scholar
• Ajili F, Kacem M, Tounsi H, Darouiche A, Enayfer E, Chebi M, et al. Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34. Ultrastruct Pathol 2012;36:336–42.
   PubMed Web of Science ®Google Scholar
• Song CW. Effect of local hyperthermia on blood-flow and microenvironment – a review. Cancer Res 1984;44:4721–30.
   PubMed Web of Science ®Google Scholar
• Chen C, Roemer RB. A thermo-pharmacokinetic model of tissue temperature oscillations during localized heating. Int J Hyperthermia 2005;21:107–24.
   PubMed Web of Science ®Google Scholar
• Kim E-C, Choi S-K, Lim M, Yeon S-I, Lee Y-H. Role of endogenous ENaC and TRP channels in the myogenic response of rat posterior cerebral arteries. PLoS one 2013;8:e84194.
   PubMed Web of Science ®Google Scholar
• Caterina MJ, Rosen TA, Tominaga M, Brake AJ, Julius D. A capsaicin-receptor homologue with a high threshold for noxious heat. Nature 1999;398(6726):436–41.
   PubMed Web of Science ®Google Scholar
• Vujaskovic Z, Poulson JM, Gaskin AA, Thrall DE, Page RL, Charles HC, et al. Temperature-dependent changes in physiologic parameters of spontaneous canine soft tissue sarcomas after combined radiotherapy and hyperthermia treatment. Int J Radiat Oncol Biol Phys 2000;46:179–85.
   PubMed Web of Science ®Google Scholar
• Jones EL, Prosnitz LR, Dewhirst MW, Marcom PK, Hardenbergh PH, Marks LB, et al. Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer. Clin Cancer Res 2004;10:4287–93.
   PubMed Web of Science ®Google Scholar
• Colombo R, Do Pozzo LF, Salonia A, Rigatti P, Leib Z, Baniel J, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003;21:4270–6.
   PubMed Web of Science ®Google Scholar
• Inman BA, Stauffer PR, Craciunescu OA, Maccarini PF, Dewhirst MW, Vujaskovic Z. A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. Int J Hyperthermia 2014;30:171–5.
   PubMed Web of Science ®Google Scholar
• Huang C, Li Y, Cao P, Xie Z, Qin Z. Synergistic effect of hyperthermia and neferine on reverse multidrug resistance in adriamycin-resistant SGC7901/ADM gastric cancer cells. J Huazhong Univ Sci Technol Med Sci 2011;31:488–96.
   PubMed Web of Science ®Google Scholar
• Alvarez-Berrios MP, Castillo A, Mendez J, Soto O, Rinaldi C, Torres-Lugo M. Hyperthermic potentiation of cisplatin by magnetic nanoparticle heaters is correlated with an increase in cell membrane fluidity. Int J Nanomed 2013;8:1003–13.
   PubMed Web of Science ®Google Scholar
• Iliakis G, Wu W, Wang M. DNA double strand break repair inhibition as a cause of heat radiosensitization: Re-evaluation considering backup pathways of NHEJ. Int J Hyperthermia. 2008;24:17–29.
   PubMed Web of Science ®Google Scholar
• Krawczyk PM, Eppink B, Essers J, Stap J, Rodermond H, Odijk H, et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci USA 2011;108:9851–6.
   PubMed Web of Science ®Google Scholar
• Mivechi NF, Dewey WC. DNA polymerase-alpha and DNA polymerase-beta activities during the cell-cycle and their role in heat radiosensitization in Chinese-hamster ovary cells. Radiat Res 1985;103:337–50.
   PubMed Web of Science ®Google Scholar
• Raoof M, Zhu C, Cisneros BT, Liu H, Corr SJ, Wilson LJ, et al. Hyperthermia inhibits recombination repair of gemcitabine-stalled replication forks. J Natl Cancer Inst 2014;106. doi: 10.1093/jnci/dju183.
   PubMedGoogle Scholar
• Alberts DS, Peng YM, Chen HSG, Moon TE, Cetas TC, Hoeschele JD. Therapeutic synergism of hyperthermia-cis-platinum in a mouse-tumor model. J Natl Cancer Inst 1980;65:455–61.
   PubMed Web of Science ®Google Scholar
• Meyn RE, Corry PM, Fletcher SE, Demetriades M. Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum(II). Cancer Res 1980;40:1136–9.
   PubMed Web of Science ®Google Scholar
• Los G, Vanvugt MJH, Pinedo HM. Response of peritoneal solid tumors after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer. 1994;69:235–41.
   PubMed Web of Science ®Google Scholar
• Los G, Vanvugt MJH, Denengelse L, Pinedo HM. Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA. Biochem Pharmacol 1993;46:1229–37.
   PubMed Web of Science ®Google Scholar
• Landon CD, Benjamin SE, Ashcraft KA, Dewhirst MW. A role for the copper transporter Ctr1 in the synergistic interaction between hyperthermia and cisplatin treatment. Int J Hyperthermia 2013;29:528–38.
   PubMed Web of Science ®Google Scholar
• Wallner KE, Li GC. Effect of drug exposure duration and sequencing on hyperthermic potentiation of mitomycin-C and cisplatin. Cancer Res 1987;47:493–5.
   PubMed Web of Science ®Google Scholar
• Mizuno S, Amagai M, Ishida A. Synergistic cell killing by anti-tumor agents and hyperthermia in cultured cells. Gann 1980;71:471–8.
   PubMedGoogle Scholar
• Nakajima K, Hisazumi H. Enhanced radioinduced cytotoxicity of cultured human bladder-cancer cells using 43-degrees-C hyperthermia or anticancer drugs. Urol Res 1987;15:255–60.
   PubMedGoogle Scholar
• Teicher BA, Kowal CD, Kennedy KA, Sartorelli AC. Enhancement by hyperthermia of the in vitro cyto-toxicity of mitomycin-C toward hypoxic tumor-cells. Cancer Res 1981;41:1096–9.
   PubMed Web of Science ®Google Scholar
• Herman TS, Teicher BA, Holden SA. Trimodality therapy (drug/hyperthermia radiation) with BCNU or mitomycin-C. Int J Radiat Oncol Biol Phys 1990;18:375–82.
   PubMed Web of Science ®Google Scholar
• Herman TS, Teicher BA, Holden SA. Addition of mitomycin-C to cis-diamminedichloroplatinum(II)/hyperthermia radiation-therapy in the FSaIIC fibrosarcoma. Int J Hyperthermia 1991;7:893–903.
   PubMed Web of Science ®Google Scholar
• Sakaguchi Y, Kohnoe S, Emi Y, Maehara Y, Kusumoto T, Sugimachi K. Cytotoxicity of mitomycin-C and carboquone combined with hyperthermia against hypoxic tumor cells in vitro. Oncology 1992;49:227–32.
   PubMed Web of Science ®Google Scholar
• Wallner KE, Banda M, Li GC. Hyperthermic enhancement of cell killing by mitomycin-C in mitomycin-C-resistant Chinese hamster ovary cells. Cancer Res 1987;47(5):1308–12.
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Sibtain A, Daley FM, Saunders MI, Wilson GD. The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma. Radiother Oncol 2004;72:159–68.
   PubMed Web of Science ®Google Scholar
• Kirui DK, Celia C, Molinaro R, Bansal SS, Cosco D, Fresta M, et al. Mild hyperthermia enhances transport of liposomal gemcitabine and improves in vivo therapeutic response. Adv Healthc Mater 2015;4:1092–103.
   PubMed Web of Science ®Google Scholar
• Adachi S, Kokura S, Okayama T, Ishikawa T, Takagi T, Handa O, et al. Effect of hyperthermia combined with gemcitabine on apoptotic cell death in cultured human pancreatic cancer cell lines. Int J Hyperthermia 2009;25:210–19.
   PubMed Web of Science ®Google Scholar
• Vertrees RA, Das GC, Popov VL, Coscio AM, Goodwin TJ, Logrono R, et al. Synergistic interaction of hyperthermia and gemcitabine in lung cancer. Cancer Biol Therapy 2005;4:1144–53.
   PubMed Web of Science ®Google Scholar
• Haveman J, Rietbroek RC, Geerdink A, Vanrijn J, Bakker PJM. Effect of hyperthermia on the cytotoxicity of 2',2'-difluorodeoxycytidine (gemcitabine) in cultured SW1573 cells. Int J Cancer 1995;62:627–30.
   PubMed Web of Science ®Google Scholar
• Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 2003;10:463–8.
   PubMed Web of Science ®Google Scholar
• Hahn GM, Braun J, Harkedar I. Thermochemotherapy – synergism between hyperthermia (42–43 degrees) and adriamycin (or bleomycin) in mammalian-cell inactivation. Proc Natl Acad Sci US A 1975;72:937–40.
   PubMed Web of Science ®Google Scholar
• Bates DA, Mackillop WJ. Hyperthermia, adriamycin transport, and cytotoxicity in drug-sensitive and drug-resistant Chinese hamster ovary cells. Cancer Res1986;46:5477–81.
   PubMed Web of Science ®Google Scholar
• Kawai H, Minamiya Y, Kitamura M, Matsuzaki I, Hashimoto M, Suzuki H, et al. Direct measurement of doxorubicin concentration in the intact, living single cancer cell during hyperthermia. Cancer 1997;79:214–19.
   PubMed Web of Science ®Google Scholar
• Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275–84.
   PubMed Web of Science ®Google Scholar
• Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human-breast cancer cells. J Biol Chem 1986;261:5544–9.
   PubMed Web of Science ®Google Scholar
• Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov 2009;8:579–91.
   PubMed Web of Science ®Google Scholar
• Franke K, Kettering M, Lange K, Kaiser WA, Hilger I. The exposure of cancer cells to hyperthermia, iron oxide nanoparticles, and mitomycin C influences membrane multidrug resistance protein expression levels. Int J Nanomed 2013;8:351–63.
   PubMed Web of Science ®Google Scholar
• Hicks KO, Pruijn FB, Secomb TW, Hay MP, Hsu R, Brown JM, et al. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst 2006;98:1118–28.
   PubMed Web of Science ®Google Scholar
• Arrick BA, Nathan CF. Glutathione metabolism as a determinant of therapeutic efficacy – a review. Cancer Res 1984;44:4224–32.
   PubMed Web of Science ®Google Scholar
• Laskowitz DT, Elion GB, Dewhirst MW, Griffith OW, Savina PM, Blum MR, et al. Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft. Radiat Res 1992;129:218–23.
   PubMed Web of Science ®Google Scholar
• Moon EJ, Sonveaux P, Porporato PE, Danhier P, Gallez B, Batinic-Haberle I, et al. NADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment. Proc Natl Acad Sci USA 2010;107:20477–82.
   PubMed Web of Science ®Google Scholar
• Mitchell JB, Russo A. Thiols, thiol depletion, and thermosensitivity. Radiat Res 1983;95:471–85.
   PubMed Web of Science ®Google Scholar
• McDaniel JR, MacEwan SR, Li XH, Radford DC, Landon CD, Dewhirst M, et al. Rational design of ‘heat seeking’ drug loaded polypeptide nanoparticles that thermally target solid tumors. Nano Lett 2014;14:2890–5.
   PubMed Web of Science ®Google Scholar
• Landon C, Park JY, Needham D, Dewhirst M. Nanoscale drug delivery and hyperthermia: The materials design and preclinical and clinical testing of low temperature sensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer. Open Nanomed J 2011;3:38–64.
   PubMedGoogle Scholar
• Zagar TM, Vujaskovic Z, Formenti S, Rugo H, Muggia F, O’Connor B, et al. Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. Int J Hyperthermia 2014;30:285–94.
   PubMed Web of Science ®Google Scholar
• Poon RTP, Borys N. Lyso-thermosensitive liposomal doxorubicin: An adjuvant to increase the cure rate of radiofrequency ablation in liver cancer. Future Oncol 2011;7:937–45.
   PubMed Web of Science ®Google Scholar
• Kneidl B, Peller M, Winter G, Lindner LH, Hossann M. Thermosensitive liposomal drug delivery systems: State of the art review. Int J Nanomed 2014;9:4387–98.
   PubMed Web of Science ®Google Scholar
• Koning GA, Eggermont AMM, Lindner LH, ten Hagen TLM. Hyperthermia and Thermosensitive Liposomes for Improved Delivery of Chemotherapeutic Drugs to Solid Tumors. Pharmaceut Res 2010;27:1750–4.
   PubMed Web of Science ®Google Scholar
• Manzoor AA, Lindner LH, Landon CD, Park JY, Simnick AJ, Dreher MR, et al. Overcoming limitations in nanoparticle drug delivery: Triggered, intravascular release to improve drug penetration into tumors. Cancer Res 2012;72:5566–75.
   PubMed Web of Science ®Google Scholar
• Dou YN, Zheng JZ, Foltz WD, Weersink R, Chaudary N, Jaffray DA, et al. Heat-activated thermosensitive liposomal cisplatin (HTLC) results in effective growth delay of cervical carcinoma in mice. J Control Release 2014;178:69–78.
   PubMed Web of Science ®Google Scholar
• Lim SK, Shin DH, Choi MH, Kim JS. Enhanced antitumor efficacy of gemcitabine-loaded temperature-sensitive liposome by hyperthermia in tumor-bearing mice. Drug Devel Ind Pharm 2014;40:470–6.
   PubMed Web of Science ®Google Scholar
• van der Heijden AG, Verhaegh G, Jansen CFJ, Schalken JA, Witjes JA. Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: An in vitro study. J Urol 2005;173:1375–80.
   PubMed Web of Science ®Google Scholar
• Loadman PM, Bibby MC, Phillips RM. Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9. Br J Pharmacol 2002;137:701–9.
   PubMed Web of Science ®Google Scholar
• Ischia J, So AI. The role of heat shock proteins in bladder cancer. Nat Rev Urol 2013;10:386–95.
   PubMed Web of Science ®Google Scholar
• Dayanc BE, Bansal S, Gure AO, Gollnick SO, Repasky EA. Enhanced sensitivity of colon tumour cells to natural killer cell cytotoxicity after mild thermal stress is regulated through HSF1-mediated expression of MICA. Int J Hyperthermia 2013;29:480–90.
   PubMed Web of Science ®Google Scholar
• Torigoe T, Hirohashi Y, Yasuda K, Sato N. Constitutive expression and activation of stress response genes in cancer stem-like cells/tumour initiating cells: Potent targets for cancer stem cell therapy. Int J Hyperthermia 2013;29:436–41.
   PubMed Web of Science ®Google Scholar
• Toraya-Brown S, Fiering S. Local tumour hyperthermia as immunotherapy for metastatic cancer. Int J Hyperthermia 2014;30:531–9.
   PubMed Web of Science ®Google Scholar
• Calderwood SK. From stress protein biochemistry to novel immunotherapeutics. Int J Hyperthermia 2013;29:362–3.
   PubMed Web of Science ®Google Scholar
• Graner MW, Romanoski A, Katsanis E. The ‘peptidome’ of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity. Int J Hyperthermia 2013;29:380–9.
   PubMed Web of Science ®Google Scholar
• Mayer-Sonnenfeld T, Har-Noy M, Lillehei KO, Graner MW. Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL’s unique structure: CRCL vaccine proteome leads to unique structure. Int J Hyperthermia 2013;29:520–7.
   PubMed Web of Science ®Google Scholar
• Repasky EA. Progress in development of biomedical applications of heat shock proteins and thermal stress. Int J Hyperthermia 2013;29:359–61.
   PubMed Web of Science ®Google Scholar
• Van Herwijnen MJC, Van der Zee R, Van Eden W, Broere F. Heat shock proteins can be targets of regulatory T cells for therapeutic intervention in rheumatoid arthritis. Int J Hyperthermia 2013;29:448–54.
   PubMed Web of Science ®Google Scholar
• Viglianti BL, Dewhirst MW, Boruta RJ, Park JY, Landon C, Fontanella AN, et al. Systemic anti-tumour effects of local thermally sensitive liposome therapy. Int J Hyperthermia 2014;30:385–92.
   PubMed Web of Science ®Google Scholar